Using cancer patients experiencing immunotherapy-triggered autoimmunity as a unique human model, this project uncovers the molecular and epigenetic mechanisms by which self-reactive T cells escape immune tolerance.
Investigating how foreign sugar modifications on anti-TNF biologics trigger immune responses in pediatric IBD patients, this project aims to personalize biologic therapy selection and inform safer drug design.
Developing a cell-labeling tool to map immune cell interactions in living tissue, this project identifies the drivers of skin-resident T cell persistence in psoriasis and potential targets for disease prevention.
Using single-molecule imaging to visualize B cell receptor signaling across gut compartments, this project uncovers how intestinal B cell education breaks down in IBD, revealing new targets for therapeutic intervention.
Identifying a novel molecular regulator of tolerogenic dendritic cell function, this project uncovers how its loss triggers spontaneous multiorgan autoimmunity and exacerbates lupus — revealing a clinically relevant pathway in immune tolerance.
A self-replicating RNA platform delivers anti-inflammatory cytokines directly to the airways, offering targeted local immune suppression without systemic toxicity — a mechanistically distinct approach to treating lupus lung disease.
Designing synthetic antigens that reprogram allergic immune memory toward durable, healthy responses — moving precision allergy vaccines toward the clinic.
Characterizing a newly discovered IgE receptor to develop it into a drug that clears circulating IgE and treats allergic diseases.
Developing an IFNγ-based molecular microscope to assess celiac disease activity and response to treatment without relying solely on diagnostic biopsies.
Developing and validating a humanized MISTRG6 mouse model that accurately replicates human immune responses to gluten for celiac disease research and drug development.
